EANS-News: Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC´s Advisory Committee on Immunization Practices

» Expanded Guidelines to include availability of IXIARO® vaccine for
Japanese Encephalitis
» IXIARO now available in the U.S. for
travelers to Asia, military
personnel, others at high risk
regardless of the length of visit

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

new product

Vienna, June 25, 2009 (euro adhoc) - Intercell AG (VSE: ICLL) today
announced that the U.S. Centers for Disease Control and Prevention
(CDC) Advisory Committee on Immunization Practices (ACIP) voted to
update its previous recommendations and include IXIARO, a new
Japanese Encephalitis (JE) vaccine for travelers to countries in Asia
where the disease is endemic, as well as Americans living in such
high-risk areas.

ACIP made significant changes to their previous Japanese Encephalitis
recommendations, last updated in 1993, noting that many more
travelers are now visiting areas where the disease is endemic. In
addition to recognizing the recent licensure of IXIARO, the
committee´s expanded recommendations urged clinicians to consider
vaccinating travelers visiting endemic areas during the transmission
season, even those on short-term visits, if they plan to spend a
substantial amount of time outdoors. The panel also concluded that
IXIARO, which is derived from a well-established cell line and does
not contain stabilizers or preservatives, has a lower risk of
vaccine-associated adverse events than older Japanese Encephalitis
vaccines.

IXIARO received marketing approval from the U.S. Food and Drug
Administration on March 30, 2009 on the basis of studies that showed
the vaccine is highly immunogenic after only two doses. IXIARO has
been shown to stimulate a long-lasting immune response and to be well
tolerated. It is the only currently manufactured Japanese
Encephalitis vaccine available in the United States. IXIARO was
developed by Intercell AG; the rights to market and distribute the
vaccine to the private sector in the United States are held by
Novartis Vaccines.

"The consequences of contracting this disease can be devastating due
to the high morbidity and mortality associated with the disease,
making IXIARO a crucial preventive tool for those spending time in
endemic areas. It is gratifying that the ACIP committee of the CDC
has chosen to broaden its recommendations and to recognize the
benefits of IXIARO," said Gerd Zettlmeissl, Chief Executive Officer
of Intercell. "This underscores our commitment to serving the needs
of the travelers´ and of the military market and developing vaccines
to address unmet needs."

The ACIP consists of 15 experts in fields associated with
immunization who have been selected by the Secretary of the U.S.
Department of Health and Human Services to provide advice and
guidance on the control of vaccine-preventable diseases. ACIP
develops written recommendations for the routine administration of
vaccines to children and adults in the civilian population. The ACIP
is the only entity in the federal government that makes such
recommendations.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market